Chicago Equity Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Chicago Equity Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$4.67M	Sell	19,630 -14,340	-42%	-$3.29M	0.47%	34
2019 Q4	$7.44M	Sell	33,970 -17,240	-34%	-$3.49M	0.43%	31
2019 Q3	$8.68M	Buy	51,210 +305	+0.6%	+$54K	0.41%	42
2019 Q2	$9.34M	Sell	50,905 -11,395	-18%	-$1.99M	0.42%	45
2019 Q1	$11.5M	Buy	62,300 +43,490	+231%	+$8.03M	0.44%	42
2018 Q4	$3.12M	Sell	18,810 -5,030	-21%	-$872K	0.13%	230
2018 Q3	$4.59M	Sell	23,840 -6,230	-21%	-$1.11M	0.14%	199
2018 Q2	$5.11M	Buy	30,070 +27,015	+884%	+$4.19M	0.16%	180
2018 Q1	$498K	Buy	+3,055	New	+$499K	0.02%	609
2017 Q4	–	Sell	-4,180	Closed	-$636K	–	839
2017 Q3	$636K	Buy	+4,180	New	+$629K	0.02%	586

Other funds holding VRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chicago Equity Partners's VRTX Position: Q1 2020 in Review

Chicago Equity Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q1 2020, selling an estimated $3.29M and leaving 19,630 shares worth $4.67M. The position accounts for 0.47% of the portfolio, ranked #34.

Chicago Equity Partners first reported a position in VRTX in Q3 2017 and has held it in 10 quarters since. The position peaked at $11.5M in Q1 2019. 855 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

Chicago Equity Partners held 19,630 shares of Vertex Pharmaceuticals worth $4.67M as of Q1 2020.
Chicago Equity Partners sold 14,340 Vertex Pharmaceuticals shares in Q1 2020, an estimated $3.29M.
Vertex Pharmaceuticals made up 0.47% of Chicago Equity Partners's portfolio in Q1 2020, its #34 holding.
Chicago Equity Partners first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 10 quarters since.
Chicago Equity Partners's Vertex Pharmaceuticals position peaked at $11.5M in Q1 2019.
855 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.